Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bayer Aktienges ADR (OP:BAYRY)

13.12 +0.21 (+1.63%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	487,581
Open	13.08
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	12.91
Today's Range	13.02 - 13.16
52wk Range	5.300 - 13.16
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Wall Street’s ‘Fear Gauge’ Reclaims the 20 Mark: Why the Greenland Tariff Threat and Earnings Redlining Triggered a Market Reset

January 20, 2026

The CBOE Volatility Index (VIX), often hailed as the stock market’s “fear gauge,” surged past the critical 20.00 threshold on January 20, 2026, marking a significant shift in investor sentiment as the...

Via MarketMinute

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

January 20, 2026

From Bayer

Via Business Wire

Performance

YTD	+18.3%	+18.3%
1 Month	+24.2%	+24.2%
3 Month	+64.6%	+64.6%
6 Month	+57.1%	+57.1%
1 Year	+139.0%	+139.0%

More News

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

Via Finterra

Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗

November 23, 2025

Via Stocktwits

Bayer Accelerates Pharma Growth on High-Value Portfolio

January 13, 2026

From Bayer

Via Business Wire

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

January 13, 2026

From Bayer

Via Business Wire

Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

January 12, 2026

From Bayer

Via Business Wire

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

January 08, 2026

From Bayer

Via Business Wire

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

January 05, 2026

From Bayer

Via Business Wire

Beyond the Bailout: US Farm Groups Demand Structural Reform as USDA Unveils $12 Billion 'Bridge' Program

January 02, 2026

Via MarketMinute

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

December 04, 2025

From Bayer

Via Business Wire

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

December 03, 2025

From Bayer

Via Business Wire

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

December 02, 2025

From Bayer

Via Business Wire

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

December 01, 2025

From Bayer

Via Business Wire

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

November 23, 2025

From Bayer

Via Business Wire

FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗

November 20, 2025

Via Benzinga

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

November 20, 2025

From Bayer

Via Business Wire

Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗

November 14, 2025

Via Benzinga

Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗

November 13, 2025

Via The Motley Fool

Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗

November 12, 2025

Via Benzinga

Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

November 10, 2025

From Bayer

Via Business Wire

KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease

November 06, 2025

From Bayer

Via Business Wire

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

October 24, 2025

From Bayer

Via Business Wire

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025

October 21, 2025

From Bayer

Via Business Wire

Frequently Asked Questions

Is Bayer Aktienges ADR publicly traded?

Yes, Bayer Aktienges ADR is publicly traded.

What exchange does Bayer Aktienges ADR trade on?

Bayer Aktienges ADR trades on the OTC Traded

What is the ticker symbol for Bayer Aktienges ADR?

The ticker symbol for Bayer Aktienges ADR is BAYRY on the OTC Traded

What is the current price of Bayer Aktienges ADR?

The current price of Bayer Aktienges ADR is 13.12

When was Bayer Aktienges ADR last traded?

The last trade of Bayer Aktienges ADR was at 01/23/26 03:59 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.